In a public notice Tuesday, Ildong said it had applied to the Ministry of Food and Drug Safety to approve the change in phase 2/3 clinical trial of an investigational new drug (IND) S-217622.

Ildong applies for changing the IND application for Covid-19 treatment

Is it time to expand access to Paxlovid, the treatment that reduces symptoms, risk of hospitalization and risk of death from COVID-19?

Paxlovid: Medical professionals eager to see criteria expanded

Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared to a placebo in a Phase III trial in Asia.

Japan's Shionogi says COVID pill reaches endpoint in Phase III trial

Recent studies have shown that patients with weakened immune systems—which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change—may enable the development of new, slightly different versions of the virus (variants).

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

The Italian Medicines Agency (AIFA) has published the results of the monitoring of antivirals currently available for treating COVID-19.

antiviral news

Press Releases in the global landscape